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Introduction:   The  calcineurin  inhibitor,  tacrolimus  (TAC),  is  widely  used  as  the  main  immunosuppression 
medication in pediatric kidney transplantation1.  It holds a narrow therapeutic index and displays wide inter-
patient variability in its pharmacokinetics.  Oral bioavailability and metabolism of TAC are dependent on efflux 
pumps found in enterocytes in the gastrointestinal tract and cytochrome P-450 (CYP) isoenzymes located both in 
the gastrointestinal tract and in the liver.  Hepatic metabolism is the principal route of TAC drug elimination.  The 
bioavailability and metabolism of TAC vary among individuals based on variation in gene expression of intestinal 
p-glycoprotein, CYP3A4 and CYP3A5, age, ethnicity, race and concomitant medication intake.    
Studies in adult kidney transplant recipients show different pharmacokinetic (PK) profiles in Caucasians 
compared  to  African  Americans  and  Asians2,  3.  However,  published  data  for  TAC  PK  in  Hispanics  is  scant 
particularly in children. Over the years we have observed a selective group of our Hispanic children after kidney 
transplantation requiring a higher mg/kg/dose of TAC or more frequent dosing (every 8 hours) to achieve our 
target therapeutic trough levels of 5-8 ng/ml.  Abbreviated TAC PK studies were done to determine optimal TAC 
dosing and frequency of administration and to rule out non adherence as a cause for the low TAC trough levels. We 
report in this retrospective analysis, our findings on TAC PK differences observed in the Hispanic vs. Non Hispanic 
patients in our pediatric transplant recipients.  
Methods:  We conducted a retrospective chart review for all pediatric patients transplanted between 2001 and 
2010 in our institution. The chart review was approved by the Institutional Review Board at our center. Twenty 
three TAC PK studies were performed as part of the clinical care in 15 pediatric kidney transplant recipients during 
that period.  All PK studies were obtained in the outpatient clinic to assist in the clinical management of patients 
who demonstrated low 12 hour trough TAC levels over time. Five patients were eventually switched to an 8 hour 
schedule for TAC dosing.  Based on their ethnicity we divided our patients into Hispanic and Non-Hispanic groups.  
All patients were on a steady state of TAC dose prior to performing the PK study. Patients were instructed to take 
their TAC dose at the usual schedule the night prior to the PK study.  Those who were on 12 hour dosing were 
instructed to take their TAC dose at 8 PM the night before the study and those who were on 8 hour dosing were to 
take their dose at midnight. An abbreviated TAC PK study  was performed using serial blood samples obtained at 0 3 
 
hour (prior to the AM dose) , then at 1, 2, 4, and 6 hours following the 8 AM oral TAC dose.  Blood TAC levels were 
analyzed by a radioimmunoassay.  
Blood  TAC  concentration-time  data  were  analyzed  by  noncompartmental  methods  (WinNonLin  5.2, 
Pharsight Inc., Mountain View, CA).  Area under the drug concentration-time curve during the dosing interval 
(AUC0-τau)  was  determined  using  the  linear  trapezoidal  rule.    Terminal  area  was  the  quotient  of  the  last 
concentration  divided  by  the  terminal  elimination  rate  constant  (z).    This  constant  was  determined  from 
regression analysis of concentration-time points in the terminal elimination phase.  AUC0-τau was added to the 
terminal area to obtain total AUC0-∞.  Maximum drug concentration (Cmax) and time to reach the maximum drug 
concentration (Tmax) were the observed values.  Terminal elimination half-life (t1/2) was calculated as 0.693/z, oral 
clearance (CL/F) was calculated as dose/AUC0-, and volume of distribution by area (VD) was calculated as CL/F/z. 
Statistical Analysis: Data between Hispanic vs non-Hispanic patients were compared using the Student’s t-
test.    Pearson-Product  Correlations  (R)  were  used  to  determine  the  relationship  between  demographic  and 
laboratory data and tacrolimus PK parameters.  Statistical significance was defined at  P < 0.05 (SigmaPlot 11, 
Systat Software Inc., San Jose, CA). 
Results:  Twenty  three  TAC  PK  studies  were  performed  in  15  patients  during  the  study  period.    Patient 
demographics and characteristics are depicted in table 1.  Five patients were on an eight hour TAC dosing (two 
were Hispanic, 40%), while the remaining 10 patients (three were Hispanic, 30%) were on a 12 hour TAC dosing 
regimen. One patient was excluded from the PK analysis because blood TAC levels remained elevated during the 
dosing interval (due to an error in performing the PK study), and hence PK parameters could not be determined 
accurately.  The Tac PK profiles for Hispanic and non-Hispanic pediatric subjects are presented in figure 1. The 
detailed TAC PK parameters in the remaining 14 patients are presented in table 2.   
When normalized to the administered dose, both the average Cmax (4.94 ±2.42 vs 6.39 ± 3.99 ng/mL/mg) 
and AUC0-∞ (32.54 ± 11.50 vs 56.56 ± 32.17 ng/mL×hr/mg) were lower in Hispanic compared to non-Hispanic 
patients (figure 1; table 2).  VD was higher in Hispanic vs non-Hispanic patients (193464 ± 88665 vs 169852 ± 
111904 mL respectively).  Oral TAC clearance was faster in Hispanic when compared to non-Hispanic patients 
(34622 ±10851 vs 25135 ±14658 mL/hr respectively), resulting in a shorter half-life (3.9 ±1.5 vs 7.9 ±12.7 hrs).   4 
 
In Hispanic patients, the measure of drug exposure-AUC increased linearly with body weight (table 3). On 
the other hand, as body weight increased, TAC clearance decreased. Similarly, as age increased, a decrease in TAC 
volume of distribution was observed.  A strong correlation was found between schwartz eGFR and TAC half-life in 
Hispanic patients.  Increased eGFR was  also associated with reductions in  TAC volume of distribution in non-
Hispanic  patients,  however  failed  to  reach  statistical  significance  (P  =  0.059).  Except  for  the  above  weak 
correlation, no other correlations were observed in non-Hispanic patients. 
The differences in the trough levels of TAC between Hispanic and non-Hispanic children are presented in 
Figure.2. Though there were only 5 Hispanic and 10 non-Hispanic subjects in this study, four patients had multiple 
PK  studies  and  hence  multiple  trough  levels  were  collected  from  them.    Large  inter  individual  variability  is 
observed in both patient groups the Hispnanic vs. non-Hispanics. 
Discussion:    The  long  term  graft  outcome  in  Hispanic  adults  with  kidney  transplantation  is  surprisingly 
comparable or superior to Caucasian and African American recipients despite many odds such as the prevalence of 
diabetes and other socioeconomic factors4.  The Hispanic Paradox is described for such a phenomenon and can be 
explained by the younger age group of the Hispanic recipients, the prevalence of living donation, the stronger 
family  support  system  and  other  factors4.  However,  these  data  are  inconclusive  for  the  Hispanic  pediatric 
recipients with few reports suggesting similar trends as the adults 5. Multiple factors may play a role in establishing 
differences in long term graft outcome among children with different ethnic backgrounds, one of which is the 
biological differences in drug metabolism and pharmacokinetics.    
Our limited retrospective analysis of TAC PK profiles in Hispanic vs. non-Hispanic children with kidney 
transplants suggests that important differences may exist in various PK parameters. However, these differences 
were not statistically significant as expected by the small sample size. Furthermore, the ability to show significant 
differences between the 2 groups was compromised by the sizable variability in PK data in the non-Hispanic group 
that included patients with Caucasian and African American races, thus accentuating the individual variability in 
TAC PK profiles in this group. Despite the large inter individual variability (figure 2), the means of trough levels of 
TAC at time 0 (just before the 8 AM morning TAC dose, appear to be similar between Hispanic and non-Hispanic 5 
 
children in figure 1. However, the similar trough levels could be misleading as some patients were on 8 hour TAC 
dosing while others were on 12 hour dosing.   
We  found  that  the  measure  of  drug  exposure  per  individual  patient  determined  by  the  AUC,  upon 
normalization to the administered dose (mg/kg or per SA), tends to be smaller in Hispanic patients. This would 
suggest that Hispanic patients require a higher dose than the non-Hispanic patients to achieve the desired drug 
exposure. Or alternatively, a more frequent dosing of the calculated normalized dose (mg/kg or BSA) may be 
warranted in Hispanic patients.  The shorter half life of TAC in Hispanics further supports the idea of using either a 
higher dose of TAC every 12 hours or more frequent dosing, i.e., every 8 hours. 
Half life is another measure of how rapidly drugs are cleared from the body which is determined by the 
status of relevant drug metabolizing enzymes and transporters. As shown in table 2, Hispanic patients exhibited a 
faster  TAC  clearance  compared  to  the  non-Hispanics.  This  could  be  due  to  the  higher  expression  of  drug 
metabolizing enzymes and/or transporters leading to faster clearance of TAC.  Cytochrome P4503A is the principal 
drug metabolizing enzyme  for TAC.  The reported ethnic variability in hepatic CYP3A activity or expression is 
inconsistent among publications and is poorly characterized in the literature. Mancinelli et al found no differences 
in intravenous TAC PK profiles in Caucasian, African American and Hispanic healthy adult volunteers3. However, 
lower intestinal bioavailability was clearly observed in African American subjects compared to the Caucasian and 
the Hispanic groups when given orally. This observation was  attributed to ethnically associated differences in 
intestinal CYP3A or P-glycoprotein activity or both rather than to hepatic CYP3A activity3. However, no data has 
been reported thus far in pediatric patients. Our study with limited sample size suggests potential differences in 
either CYP3A or Pgp or both between Hispanic and non-Hispanic children. This preliminary observation needs to 
be followed up with a larger study. 
The  significant  correlation  of  body  weight  to  TAC  clearance  in  Hispanic  children  is  an  interesting 
observation while such correlation is absent in non-Hispanic children. This finding is relevant especially given the 
higher rate of obesity in hispanic children compared to non-hispanic children. Obesity is considered to be a pro-
inflammatory condition with elevated levels of plasma cytokines 6 which are known modulators of the expression 
of  various  Cytochrome  P450  enzymes  including  Cytochrome  P4503A  in  adults7-9.  Our  study  extends  this 
observation  to  children; though  it is not  clear  to  the  authors  why  this  observation is found  only in  Hispanic 6 
 
children. Similar to body weight correlation to TAC clearance, the strong correlation between age and volume of 
distribution  of  TAC  is  observed  only  in  Hispanic  children.  Aging  related  changes  in  drug  pharmacokinetics, 
including distribution is well studied in adults and children10. Age associated changes in body mass and protein 
binding is shown to decrease volume of distribution for water-soluble drugs, and an increase for lipophilic drugs. 
TAC is a poorly water-soluble drug11, and therefore the authors expected an increase in TAC volume of distribution.  
On the contrary, we have observed a lack of correlation in non-Hispanic children, and more surprisingly a decrease 
in non-Hispanic children.  TAC is very highly bound to erythrocytes and plasma proteins mainly lipoproteins12. Any 
increases in the plasma concentrations of lipoproteins could increase the amount of drug bound to plasma proteins 
leading to a decrease in volume of distribution. Plasma concentrations of small dense LDL and lipoprotein-a are 
higher  in  adult Hispanics  compared  to  non-Hispanic  adults13.  Though,  similar  comparisons  are  unavailable  in 
children, extrapolating adult comparisons to children could potentially explain our observation. Our hypothesis is 
based on a small sample size and begs confirmation using a large sample study. 
The limitation of this small retrospective analysis is that it included only those patients with problems 
achieving adequate target TAC trough levels. Selection bias may have played a role in our final results however the 
propensity of Hispanics in this group of patients lead us to hypothesize that there might be true differences based 
on  ethnic  background.    In  addition,  due to  the  sample  size,  this  study  has not  considered  other  independent 
variables such as age of pediatric patient which was shown to be inversely correlated to TAC dose14. Given these 
limitations, our study stresses the need for a large prospective study in pediatric population to understand ethnic 
differences in TAC pharmacokinetics. In summary, we found that a number of our Hispanic children post kidney 
transplantation exhibited lower AUC for a TAC dose when adjusted for weight or surface area, and larger volume of 
distribution, thus requiring higher or more frequent dosing of TAC. Clinicians may elect to perform TAC PK studies 
in Hispanic children who fail to achieve target TAC trough levels post kidney transplantation.      
REFERENCES: 
1.  Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999;10:1366. 
2.  Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic 
differences. Int J Clin Pharmacol Ther 2004;42:701. 
3.  Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a 
comparison across ethnic groups. Clin Pharmacol Ther 2001;69:24. 7 
 
4.  Gordon EJ, Caicedo JC. Ethnic advantages in kidney transplant outcomes: the Hispanic Paradox at work? Nephrol 
Dial Transplant 2009;24:1103. 
5.  Jarzembowski T, John E, Panaro F, et al. Impact of non-compliance on outcome after pediatric kidney 
transplantation: an analysis in racial subgroups. Pediatr Transplant 2004;8:367. 
6.  Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in 
expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. 
Circulation 2008;117:2253. 
7.  Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999;88:1. 
8.  Hunt CM, Watkins PB, Saenger P, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. 
Clin Pharmacol Ther 1992;51:18. 
9.  Hunt CM, Westerkam WR, Stave GM, Wilson JA. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. 
Mech Ageing Dev 1992;64:189. 
10.  Birnbaum LS. Pharmacokinetic basis of age-related changes in sensitivity to toxicants. Annu Rev Pharmacol 
Toxicol 1991;31:101. 
11.  Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug: 
the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 2002;91:719. 
12.  Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ. Validation of methods to study the distribution and 
protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods 2001;46:27. 
13.  Watson KE. Plasma lipoprotein concentrations in ethnic populations. Curr Cardiol Rep 2003;5:483. 
14.  Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti Vehaskari V. Effect of age, ethnicity, and glucocorticoid use 
on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005;9:162. 